2005•Annals of HematologyRequires access

A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group

Agata Wrzesień‐Kuś, Tadeusz Robak, Agnieszka Wierzbowska, Ewa Lech‐Marańda, Agnieszka Pluta, Ewa Wawrzyniak, Anna Krawczyńska, Kazimierz Kuliczkowski, Grzegorz J. Mazur, M. Kiebiński, Anna Dmoszyńska, Małgorzata Wach, Andrzej Hellmann, Wojciech Baran, Jerzy Hołowiecki, Sławomira Kyrcz‐Krzemień, Sebastian Grosicki

Open publisher page 42 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 42 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Cladribine, Mitoxantrone, Cytarabine, Medicine, Internal medicine, Regimen, Granulocyte colony-stimulating factor, Gastroenterology